Widespread annual Covid-19 booster jabs are “not a good use” of taxpayer cash, according to the chief executive of AstraZeneca.
Pascal Soriot told The Telegraph that research suggests the vaccine gives healthy people protection against severe disease for a “long time”, meaning most will not need a top-up jab to avoid severe complications from the virus.
AstraZeneca’s vaccine is still not being used in many Western booster roll-outs, despite data showing it works, with many countries preferring mRNA vaccines made by Moderna and Pfizer.
